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Amyotrophic lateral sclerosis and frontotemporal dementia are two progressive, adult
onset neurodegenerative diseases, caused by the cell death of motor neurons in the
motor cortex and spinal cord and cortical neurons in the frontal and temporal lobes,
respectively. Whilst these have previously appeared to be quite distinct disorders, in
terms of areas affected and clinical symptoms, identification of cognitive dysfunction
as a component of amyotrophic lateral sclerosis (ALS), with some patients presenting
with both ALS and FTD, overlapping features of neuropathology and the ongoing
discoveries that a significant proportion of the genes underlying the familial forms of
the disease are the same, has led to ALS and FTD being described as a disease
spectrum. Many of these genes encode proteins in common biological pathways
including RNA processing, autophagy, ubiquitin proteasome system, unfolded protein
response and intracellular trafficking. This article provides an overview of the ALS-FTD
genes before summarizing other known ALS and FTD causing genes where mutations
have been found primarily in patients of one disease and rarely in the other. In discussing
these genes, the review highlights the similarity of biological pathways in which the
encoded proteins function and the interactions that occur between these proteins, whilst
recognizing the distinctions of MAPT-related FTD and SOD1-related ALS. However,
mutations in all of these genes result in similar pathology including protein aggregation
and neuroinflammation, highlighting that multiple different mechanisms lead to common
downstream effects and neuronal loss. Next generation sequencing has had a significant
impact on the identification of genes associated with both diseases, and has also
highlighted the widening clinical phenotypes associated with variants in these ALS and
FTD genes. It is hoped that the large sequencing initiatives currently underway in ALS
and FTD will begin to uncover why different diseases are associated with mutations
within a single gene, especially as a personalized medicine approach to therapy, based
on a patient’s genetics, approaches the clinic.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is an adult onset
neurodegenerative disorder caused by progressive loss of
upper motor neurons in the motor cortex and brainstem and
lower motor neurons in the spinal cord (Hardiman et al., 2017).
It has an incidence of 2–3 per 100,000 and a lifetime risk of
1 per 400 individuals (Brown and Al-Chalabi, 2017). Disease
onset occurs most frequently in the limbs, characterized by a loss
of dexterity in the fingers or a mild limp, whilst bulbar onset,
which occurs in 20–25% of cases, is characterized by a slurring
of speech (dysarthria) or difficulty swallowing (dysphagia). Less
than 3% of cases are due to respiratory onset, with shortness of
breath (dyspnea) being the most common symptom (Gautier
et al., 2010). As the disease rapidly progresses, muscle wasting,
fasciculations and weight loss occur, with death usually due
to respiratory failure 32 months following symptom onset
(Cooper-Knock et al., 2013).
Amyotrophic lateral sclerosis clinical features may also be
accompanied by cognitive impairment in up to 50% of patients,
whilst up to 15% may develop symptoms which are clinically
diagnosed as frontotemporal dementia (FTD), resulting in a
clinical diagnosis of ALS-FTD (Nguyen et al., 2018). FTD is
the second most common form of presenile dementia after
Alzheimer’s disease, accounting for 3–26% of cases of dementia
in individuals under 65 years of age, depending on population
(Bang et al., 2015). Whilst FTD is a clinical diagnosis, evidence
of degeneration of the neurons in the frontal and temporal
lobes upon post-mortem allows the pathological diagnosis of
frontotemporal lobar degeneration (FTLD) (Mackenzie and
Neumann, 2016). FTD can be divided into three different clinical
subtypes. Behavioral variant FTD (bvFTD) is characterized by
personality changes such as disinhibited behavior, apathy and loss
of empathy. In contrast, semantic variant primary progressive
aphasia (svPPA or svFTD) is characterized by individuals having
difficulties understanding the meaning of words or naming
objects or people, whereas non-fluent variant PPA (nfvPPA or
nfvFTD) is when individuals have difficulties in pronunciation,
grammar and fluency of speech (Bang et al., 2015).
Whilst the majority of ALS and FTD cases are sporadic (sALS
and sFTD), with no family history of disease, in around 10% of
cases ALS is inherited, usually in an autosomal dominant manner
with an adult onset (fALS) (Brenner and Weishaupt, 2019). In
FTD, it is estimated that 10–30% shows autosomal dominant
inheritance (fFTD), though this figure may be increased to
approximately 40% when a history of neurodegenerative disease
is included (Sirkis et al., 2019). To date, 5 ALS-FTD genes have
been recognized along with 24 ALS-associated genes and 3 FTD-
associated genes (Table 1). This review will firstly summarize the
genes that have been recognized as ALS-FTD genes (defined as
FTDALS loci on Online Mendelian Inheritance in Man1) before
summarizing other known ALS and FTD causing genes where
mutations have been found primarily in patients of one disease
and rarely in the other. Finally, a brief comment on the other
ALS and FTD genes allocated an ALS or FTD loci number
1https://www.ncbi.nlm.nih.gov/omim
is provided for completeness and to highlight the similarity
of biological pathways that are implicated in both disorders,
supporting the proposal that these two disorders represent either
end of a disease spectrum. Whilst some of these genes result in
Mendelian inheritance of ALS, others act as risk factors. However,
understanding why a particular mutation in a gene leads to ALS,
FTD or both, currently remains unknown.
ALS-FTD GENES
Mutations in five genes have been recognized as being
implicated in ALS-FTD families. These are the GGGGCC (G4C2)
hexanucleotide repeat expansion (HRE) in C9orf72 (FTDALS1),
and missense and/or loss of function mutations in CHCHD10
(FTDALS2), SQSTM1 (FTDALS3), and TBK1 (FTDALS4). In
addition, CCNF has also been reported as an ALS-FTD gene and
is referred in this review as FTDALS5. All of these genes encode
proteins with a function in autophagy, except CHCHD10, which
localizes to the mitochondria.
FTDALS1: Chromosome 9 Open Reading
Frame 72 (C9orf72)
Linkage and genome wide association studies in several families
presenting with ALS/FTD, ALS or FTD revealed the diseases
to segregate with a locus on chromosome 9p21 (Morita et al.,
2006; Vance et al., 2006; Laaksovirta et al., 2010; Shatunov
et al., 2010). In 2011, the pathogenic G4C2 hexanucleotide repeat
expansion (HRE) in intron 1 of chromosome 9 open reading
frame 72 (C9orf72) (Figure 1) was found to be the most common
cause of familial ALS and FTD (DeJesus-Hernandez et al., 2011;
Renton et al., 2011) with ∼40% fALS and 25% fFTD carrying
the C9orf72 repeat expansion (Majounie et al., 2012). However,
the frequency of C9orf72-related ALS-FTD (and C9orf72-ALS
and C9orf72-FTD) patients positive for the presence of repeat
expansion in C9orf72 varies between different populations and
ethnicities; whilst the C9orf72 G4C2 HRE is the most frequent
cause of ALS-FTD, ALS and FTD in European and North
American populations, it was found to be extremely rare in
Asia and the Middle East (Majounie et al., 2012). Whilst it is
currently unclear why some patients with the C9orf72 expansion
develop ALS or FTD while others manifest a combination of
both, the discovery of C9orf72 in causing both ALS and FTD has
strengthened the genetic link between these neurodegenerative
disorders. C9orf72-related ALS-FTD has an autosomal dominant
mode of inheritance with evidence of incomplete penetrance
(Majounie et al., 2012). Anticipation has been reported in some
families (Gijselinck et al., 2016; Van Mossevelde et al., 2017b),
however, this phenomenon has been found to be inconsistent,
with other studies having reported no association between age
of onset and repeat length (Dols-Icardo et al., 2014) or even
an inverse correlation between expansion size and age of onset
in successive generations, with contractions in the repeat size
also reported in subsequent generations (Fournier et al., 2019;
Jackson et al., 2020). Some of these contradictory findings may
be attributed to the age at collection of sample, owing to the
dynamic nature of repeat size relative to age, the methodology
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TABLE 1 | Overview of known ALS-FTD, ALS, and FTD loci.
ALS Loci number Chromosomal
location
Gene Onset Inheritance Implicated pathogenic mechanisms Original References
ALS-FTD genes
FTDALS1 9p21.2 C9orf72 Adult AD RNA processing; nucleocytoplasmic transport
defects; proteasome impairment; autophagy;
inflammation; protein aggregation (DPRs)
DeJesus-Hernandez
et al., 2011; Renton
et al., 2011
FTDALS2 22q11.23 CHCHD10 Adult AD Mitochondrial function, synaptic dysfunction Bannwarth et al., 2014
FTDALS3 5q35.3 SQSTM1 Adult AD Proteasome impairment; autophagy; protein
aggregation; axonal defects; oxidative stress
Fecto et al., 2011
FTDALS4 12q14.2 TBK1 Adult AD Autophagy; inflammation; mitochondrial
dysfunction
Cirulli et al., 2015;
Freischmidt et al., 2015
FTDALS5 16p13.3 CCNF Adult AD Autophagy, axonal defects, protein aggregation Williams et al., 2016
Predominantly ALS genes also found with FTD
ALS6 16p11.2 FUS Adult AD (AR) RNA processing; nucleocytoplasmic transport
defects; stress granule function; protein
aggregation
Kwiatkowski et al.,
2009; Vance et al.,
2009
ALS10 1p36.22 TARDBP Adult AD RNA processing; nucleocytoplasmic transport
defects; stress granule function; protein
aggregation
Sreedharan et al., 2008
ALS12 10p13 OPTN Adult AD (AR) Autophagy; protein aggregation; inflammation Maruyama et al., 2010
ALS15 Xp11.21 UBQLN2 Adult X-LD Proteasome impairment; autophagy; protein
aggregation; oxidative stress; axonal defects
Deng et al., 2011
ALS22 2q35 TUBA4A Adult AD Cytoskeleton Smith et al., 2014
ALS13 12q24.12 ATXN2 Adult AD RNA processing Elden et al., 2010
Predominantly FTD genes also found with ALS
ALS14 9p13.3 VCP Adult AD Autophagy; proteasome impairment; defects in
stress granules; protein aggregation;
mitochondrial dysfunction
Johnson et al., 2010
ALS17 3p11.2 CHMP2B Adult AD Autophagy; protein aggregation Parkinson et al., 2006
Known ALS genes
ALS1 21q22.11 SOD1 Adult AD (AR) Oxidative stress; protein aggregation;
mitochondrial dysfunction, axonal defects,
proteasome impairment apoptosis
Rosen et al., 1993
ALS2 2q33.1 ALS2 Juvenile AR Intracellular trafficking Hadano et al., 2001;
Yang et al., 2001
ALS4 9q34.13 SETX Juvenile AD RNA processing Chen et al., 2004
ALS5 15q21.1 SPG11 Juvenile AR Axonal defects Orlacchio et al., 2010
ALS8 20q13. 32 VAPB Adult AD Proteasome impairment; intracellular trafficking Nishimura et al., 2004
ALS9 14q11.2 ANG Adult AD RNA processing Greenway et al., 2006
ALS11 6q21 FIG4 Adult AD Intracellular trafficking Chow et al., 2009
ALS16 9p13.3 SIGMAR1 Juvenile AD and AR Proteasome impairment; intracellular trafficking Luty et al., 2010;
AL-Saif et al., 2011
ALS18 17p13.2 PFN1 Adult AD Axonal defects Wu et al., 2012
ALS19 2q34 ERBB4 Adult AD Neuronal development Takahashi et al., 2013
ALS20 12q13.13 hnRNPA1 Adult AD RNA processing Kim et al., 2013
ALS21 5q31.2 MATR3 Adult AD RNA processing Johnson et al., 2014
ALS23 10q22.2 ANXA11 Adult AD Intracellular trafficking Smith et al., 2014
ALS24 4q33 NEK1 Adult AD Intracellular trafficking Brenner et al., 2016
ALS25 12q13.3 KIF5A Adult AD Axonal defects; intracellular trafficking Nicolas et al., 2018
ALS 3p21.1 GLT8D1 Adult AD Ganglioside synthesis Cooper-Knock et al.,
2019
Known FTD genes
FTD 17q21.2 MAPT Adult AD Axonal defects, protein aggregation Hutton et al., 1998
FTD 17q21.31 GRN Adult AD Inflammation; protein aggregation Baker et al., 2006;
Cruts et al., 2006
FTD 6q27 TBP Adult AD RNA processing Olszewska et al., 2019
AD, autosomal dominant; AR, autosomal recessive; X-LD, X-linked inheritance.
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used and the source of samples being compared (peripheral
blood versus brain autopsy tissue) (van Blitterswijk et al., 2013a;
Fournier et al., 2019).
Although, the exact cut-off for repeat size that would result in
pathogenicity has not been clearly defined, neurologically healthy
non-carriers typically present with less than 20 repeats, while
repeat expansion mutation carriers show more than 30 repeats
on repeat primed PCR (Renton et al., 2011). Southern blotting of
the region has estimated that repeat lengths of several hundred to
several thousand are associated with C9orf72-related ALS-FTD,
though smaller repeat sizes have been found to co-segregate with
disease (Van Mossevelde et al., 2017a). Conventional techniques
such as short-read next generation sequencing (NGS) limit
accurate repeat sizing of the larger repeats, and somatic instability
has been reported, thereby contributing to the variability in
repeat size in different tissues from the same individual, such
as in comparisons between blood and central nervous system
(CNS) tissue (Vatsavayai et al., 2019). Studies have described an
inverse relationship between repeat expansion size and disease
duration withC9orf72-related ALS-FTD presenting an earlier age
of symptom onset, a higher incidence of bulbar onset and shorter
disease duration (Majounie et al., 2012; van Blitterswijk et al.,
2013b; Suh et al., 2015; Trojsi et al., 2019). However, other studies
have also reported disease durations between 1 and 22 years
(Majounie et al., 2012; Woollacott and Mead, 2014). Sex has been
reported to be a risk factor in driving phenotype with one study
showing females have a higher prevalence for C9orf72 HRE in
ALS in a meta-analysis study (Trojsi et al., 2019) whilst males
presented with a shorter survival time based on Cox proportional
hazard regression multivariate analysis (Curtis et al., 2017). It
is noteworthy that C9orf72 repeat expansions have been shown
to be associated with a number of neurodegenerative conditions
including Parkinson disease, Alzheimer’s disease, Huntington-
disease like syndrome among others (Woollacott andMead, 2014;
Cooper-Knock et al., 2015c).
The function of endogenous C9orf72 protein is not fully
characterized although it has been identified as a guanine
exchange factor (GEF), with both Rho and Rab-GTPase GEF
activity (Iyer et al., 2018). It has also been shown that the
C9orf72 protein interacts with the Rab1a and Unc-51-like kinase
1 (ULK1) autophagy initiation complex, with the C9orf72 protein
regulating the trafficking of the ULK1 complex to the phagophore
(Webster et al., 2016). As such, a reduction in C9orf72 protein
would lead to reduced autophagy and accumulation of p62-
positive aggregates, similar to those seen upon neuropathological
examination of patients.
Whilst the exact mechanism of action of how the HRE in
C9orf72 causes neurodegeneration remains to be fully elucidated,
three mutually compatible mechanisms have been proposed
including haploinsufficiency of endogenous C9orf72 protein, loss
of function and/or toxic gain of function following the formation
of RNA foci and toxic gain of function of the dipeptide repeat
(DPR) protein inclusions (Figure 1).
Haploinsufficiency of C9orf72
The C9orf72 gene contains 12 exons (1a, 1b, 2–11) and
has three well characterized transcripts which produce two
protein isoforms (Figure 1) (Balendra and Isaacs, 2018) though
additional alternatively spliced and protein coding transcripts
have been identified (see Ensembl ENSG00000147894). The HRE
is located in the pre-mRNA transcript of variant 1 and 3 but in
the promoter region of variant 2. It is noteworthy that variants
1 and 3 are predominantly expressed in the brain. Additionally,
HRE dependent epigenetic changes such as hypermethylation
of the C9orf72 gene locus has been reported and associated
with disease duration and advanced age of onset (Nordin et al.,
2015; Gijselinck et al., 2016; Zhang M. et al., 2017). Studies
have shown that transcript sequences upstream of the repeat
are increased relative to those downstream which might imply
that the transcription was aborted due to the presence of repeat.
Consequently, reduced levels of the transcript variants have been
reported in blood lymphocytes (Ciura et al., 2013), induced
pluripotent stem cells (iPSCs)-derived neurons (Shi et al., 2018)
and post mortem tissue of C9orf72-related ALS and FTD patients
(van Blitterswijk et al., 2013b). C9orf72 knockdown in zebrafish
was shown to produce defective axon generation and motor
deficits (Ciura et al., 2013) indicating that C9orf72 protein might
play a role in neuronal health. In contrast, specific knockdown
of C9orf72 in mouse brain by antisense oligonucleotides (Lagier-
Tourenne et al., 2013) or full ablation of C9orf72 (C9orf72−/−)
in neuron-specific (Atanasio et al., 2016) or all tissues (Sudria-
Lopez et al., 2016) in mice models showed no neurodegenerative
phenotype, although ablated mice developed an autoimmune
phenotype and showed reduced survival. This suggests that
haploinsufficiency alone may not be sufficient to cause disease
and a combination of aberrant pathways such as gain of toxic
function with loss of endogenous C9orf72 protein functionmight
therefore be required for disease pathogenesis.
RNA Foci Formation
The hexanucleotide repeat DNA sequences are bidirectionally
transcribed resulting in the production of G4C2 sense and
C2G4 antisense transcripts retaining the repeat expansions.
Hexanucleotide repeat-retaining RNA forms secondary
structures (such as a G-quadruplex) in which the abnormal
RNA accumulate to form RNA foci. These RNA foci have
been shown to be present in post-mortem brain and spinal
cord tissues of C9orf72-related ALS-FTD patients whilst being
absent in age-matched non-ALS/FTD neurologically healthy
controls (Zu et al., 2013). Sense and antisense RNA transcripts
get transported to the cytoplasm and have been detected in the
cytoplasm of patient post mortem tissue (Mizielinska et al., 2013;
Cooper-Knock et al., 2015b) and RNA foci have been found
in many cell lines and patient biosamples, such as leukocytes,
fibroblasts, and iPSC-derived motor neurons (Gendron and
Petrucelli, 2018). The aggregation of RNA foci are dynamic
and result from association and dissociation of RNA binding
proteins (RBPs) which results in loss of their function. Research
has shown that antisense foci were observed to be higher in the
Purkinje neurons in cerebellum and motor neurons whereas
sense foci were significantly increased in the granule neurons in
the cerebellum obtained post mortem from C9orf72-related ALS
orC9orf72-related ALS-FTD patients, as detected by fluorescence
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FIGURE 1 | Structure of the C9orf72 gene (a) and the proposed mechanisms of C9orf72 related toxicity in driving ALS/FTD pathogenesis (b–d). (a) C9orf72 has 11
exons and is transcribed into three different mRNA transcripts: variant 1 results in translation of the short protein isoform while variants 2 and 3 both generate the
long protein isoform. The non-coding introns are represented in orange and the coding exons are shown in blue. The hexanucleotide repeat expansion is present
within intron 1 region and is retained in the pre-mRNA transcript in variants 1 and 3 whereas it is present in the promoter region in variant 2. The G4C2 HRE is
proposed to cause neurotoxicity by three mutually compatible mechanisms. (b) Haploinsufficiency of endogenous C9orf2 protein by incorporation of the repeat in
the transcript leading to reduced production and function of normal C9orf72 protein. (c) RNA mediated toxicity by the formation of RNA foci that sequester RNA
binding proteins (RBPs) and (d) DPR mediated toxicity resulting from repeat associated non-AUG (RAN) translation of mRNA transcripts retaining hexanucleotide
repeats thus generating five different dipeptide repeat (DPR) products.
in situ hybridization (Cooper-Knock et al., 2014, 2015b) and
RT-PCR (Zu et al., 2013).
Several studies have aimed to identify the RBPs that
are sequestered within the C9orf72 RNA foci and have
found hnRNPA1/3, PUR-a, ADARB2, Nucleolin, SRSF2, and
ALYREF in post mortem CNS tissue, iPSCs-derived cortical
neurons reprogrammed from C9orf72-related ALS-FTD patient
fibroblasts, neuronal cell lines or a Drosophila model of C9orf72
ALS (Donnelly et al., 2013; Sareen et al., 2013; Cooper-Knock
et al., 2014; Hautbergue et al., 2017). Gene ontology and
transcriptomic analyses have revealed that the formation of foci
result in transcriptional profiles unique to C9orf72-related ALS
and FTD when compared to other genetic causes of ALS and
FTD. Changes in gene expression are associated with various
cellular pathways including unfolded protein response (UPR),
RNA splicing, inflammatory response, cell signaling and synaptic
transmission (Cooper-Knock et al., 2015a; Prudencio et al., 2015).
Taken together, these studies provide evidence for both a loss of
function of the RNA binding proteins and a potential gain of toxic
function of the downstream effects of the RNA foci formation in
driving C9orf72-related ALS-FTD pathogenesis.
Toxicity by DPR
The C9orf72 HRE sense and antisense RNA transcripts can get
translated by a non-canonical mechanism of repeat associated
non-ATG (RAN) translation resulting in the production of
dipeptide repeats. RAN translation occurs in the absence of
an AUG start codon resulting in multiple reading frames of
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a single repeat transcript. These DPRs can be generated from
the sense and/or antisense transcripts resulting in the formation
of five different products: poly-GA and poly-GR are translated
from the sense GGGGCC strand whereas poly-PA and poly-
PR are translated from the antisense CCGGGG strand; poly-
GP is translated from both strands. DPRs have been shown to
aggregate in the cytoplasm and appear as star-shaped inclusions
in both neurons and glia (Mann et al., 2013; Schludi et al., 2015).
Sense-derived poly-GA aggregated seem to be more frequent
than others, however, both sense and antisense DPRs have been
observed in neocortex, hippocampus, and thalamus (Cooper-
Knock et al., 2012; Schludi et al., 2015). poly-GA and poly-PR
inclusions were found to be more frequent in the granular
layer of cerebellum and CA3/4 regions, respectively, in C9orf72-
FTD compared to C9orf72-ALS and C9orf72-related ALS-FTD
patients (Schludi et al., 2015). In contrast, DPRs were rarely
observed in the brainstem and spinal cord. Arginine rich DPRs
(poly-PR and poly-GR) have been documented to be toxic and
contributory to neurodegeneration although these studies were
performed on primary neuronal cultures and animal models
(May et al., 2014; Mizielinska et al., 2014; Moens et al., 2017).
DPR inclusions stain positive for p62 (SQSTM1), which is a
component of ubiquitin-proteasome system (and which is also
mutated in ALS-FTD) whilst TDP-43 pathology is found to be
variable, with TDP-43 inclusions not always present in the same
neurons as DPR inclusions (Cooper-Knock et al., 2012, 2015a;
Mann et al., 2013; Schludi et al., 2015; Hautbergue et al., 2017).
In a Drosophila model of C9orf72-related ALS and FTD, it
was demonstrated that neurodegeneration was mediated through
DPRs rather than RNA foci (Mizielinska et al., 2014; Tran
et al., 2015). Firstly, only pure repeats rather than stop-codon
interrupted “RNA only” repeats led to a neurodegenerative-like
phenotype in the flies (Mizielinska et al., 2014). A second study
generated several uninterrupted repeat constructs including 5,
12, 40, and 160 G4C2 repeats with flanking intron and exon
sequences (Tran et al., 2015). Although the fly expressing this
160 G4C2 repeat formed abundant RNA foci in neurons and
glia, no DPR were produced and it did not develop neurotoxicity
(Tran et al., 2015). In contrast, BAC transgenic mice models of
C9orf72-related ALS-FTD showed RNA foci and DPR inclusions
without development of a neurodegenerative-like phenotype or
behavioral abnormalities (O’Rourke et al., 2015; Peters et al.,
2015). Recently, a DPR-only mouse expressing poly(GA)149
conjugated to cyan fluorescent protein developed p62-positive
poly-GA inclusions in motor neurons and interneurons of spinal
cord, brain stem and in cerebellar nuclei, with motor deficits
occurring at 4 months. However, there was no impairment to
learning and memory (Schludi et al., 2017).
Expansions of G4C2 which are translated to form DPRs have
been shown inDrosophilamodels and C9orf72-ALS iPSC derived
neurons to disrupt nucleocytoplasmic transport (NCT), both
export of nuclear RNA and import of nuclear proteins, through
binding to many of the nuclear pore complex proteins (Freibaum
et al., 2015). RanGAP, a key regulator of nucleocytoplasmic
transport, was found to bind to both the G4C2 RNA and the DPR
protein poly(GA) thereby causing defective nucleocytoplasmic
transport in Drosophila and mouse models of C9orf72-ALS and
iPSC derived neurons (Zhang et al., 2015, 2016). Poly(PR) and
poly(GR) were also found to interact with RNA binding proteins
and other low complexity domain proteins, including those in
the nuclear pore complex (Lee et al., 2016) and using Xenopus
laevis oocytes, poly(PR) was shown to bind and block the central
channel of the pore (Shi et al., 2017). However, in the SHSY-5Y
neuronal cell line and iPSC-derived neurons, it was shown that
poly(GR) and poly(PR) had no effect on active nucleocytoplasmic
transport, though poly(GA) deficits were observed (Vanneste
et al., 2019). Thus, there are likely to be specific pathogenic
mechanisms associated with the different DPRs.
In summary, many studies have been conducted to
elucidate the pathogenesis of the C9orf72 HRE in causing
neurodegeneration and cognitive dysfunction without obtaining
clear conclusions. Several factors including background of the
animal studies, overexpression of mutation and experimental
design can contribute to the variable results. It remains to be
determined whether loss of C9orf72 protein function and toxic
gain of function by RNA foci formation and DPR inclusion act
in a concerted manner to manifest neurodegeneration in ALS
and patient-derived cell models may be a more appropriate
model for addressing these questions as they carry the HRE
in a natural genetic context and the protein is expressed at
physiological levels. However, a recent paper described that
knocking down one or both endogenous C9orf72 alleles in
transgenic mice expressing either 66 repeats or 450 repeats
led to reduced autophagy and enhanced DPR accumulations,
cognitive deficits, hippocampal neuron loss and glial activation
(Zhu et al., 2020). Thus, this work demonstrated that there is a
synergy between the loss of C9orf72 protein and the toxic gain
of function mechanisms. In addition, these mechanisms offer
targets for novel therapeutics and the antisense oligomer strategy
currently in clinical trials may offer a disease-modifying therapy.
FTDALS2: Coiled-Coil Helix Coiled-Coil
Helix Domain Containing Protein 10
(CHCHD10)
CHCHD10 was initially associated with ALS when it was
shown to segregate with disease in a family presenting with
a complex phenotype including ALS, FTD, cerebellar ataxia,
and myopathy (Bannwarth et al., 2014). Subsequently, several
cohorts of ALS and ALS-FTD patients were screened for
CHCHD10 mutations and a number of candidate rare, predicted
deleterious mutations were identified (Johnson et al., 2014; Dols-
Icardo et al., 2015). However, it has been shown more recently
that many of the proposed mutations are present at similar
frequency in controls (Marroquin et al., 2016), perhaps because
exome sequencing studies typically give poor coverage of the
CHCHD10 gene which leads to a propensity for false positives.
Whole genome sequencing, where coverage of the CHCHD10
is complete, revealed that there was no significant burden of
disease-associated mutations in sporadic ALS patients (Project
MinE ALSSC, 2018). In fact, with increased coverage of control
cohorts most of the ALS-associated mutations have been found
at comparable frequency in controls despite in vitro and in vivo
evidence for toxicity. Of the remaining mutations there is a
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notable association with complex phenotypes including motor
neuron degeneration but not typical ALS. The exception is
c.44G > T (p.Arg15Leu) which has been identified in both
sporadic and familial ALS cases with variable penetrance but is
virtually absent in control databases (ProjectMinEALSSC, 2018).
Some of these cases have additional phenotypes such as hearing
loss which may represent a distinct pathogenic process. However,
assessment of TDP-43 pathology in these cases, which is arguably
the molecular hallmark of ALS, is not yet available. CHCHD10
is localized to the mitochondria and patients with mutations in
CHCHD10 demonstrated abnormal mitochondrial morphology
and respiratory chain deficiencies (Bannwarth et al., 2014).
FTDALS3: Sequestosome 1 (SQSTM1):
SQSTM1, also known as p62, is a ubiquitin binding protein
that is present in a variety of ubiquitinated inclusions associated
neurodegenerative diseases including ALS and FTD. Mutations
in this gene were originally associated with Paget’s disease of
bone (PDB), a progressive skeletal disorder associated with an
increased bone turnover producing localized lesions and bone
pain (Rea et al., 2014). Missense mutations in the ubiquitin
associated domain (UBA) or truncation mutations that cause
partial or complete remove of the UBA account for 25–50%
of familial PDB and 5–10% of sporadic PDB. However, the
mutations in SQSTM1 associated with ALS, FTD, and ALS-FTD
cases are found throughout the gene, including the UBA, thereby
impacting on many of the other pathways that the SQSTM1
protein participates in Rea et al. (2014). Functional domains
include a light chain 3 (LC3) interacting region (LIR) that
interacts with LC3 to promote autophagy, a KEAP1 interacting
region (KIR) which binds KEAP1 competitively with NRF2
to regulate oxidative stress response and the PB1 domain,
that interacts with several proteins which impact on neuronal
survival and inflammation (Ma et al., 2019). Whilst SQSTM1
mutations have been found in individuals who also carry a
C9orf72 expansion (Almeida et al., 2016; Kovacs et al., 2016),
the pathogenicity of SQSTM1 mutations has been demonstrated
in zebrafish, which showed behavioral abnormalities as well as
disrupted autophagy and shorter axons following knockdown of
the SQSTM1 ortholog. Importantly, these features were rescued
by human SQSTM1 protein but not by the p.P392L common
SQSTM1 mutation (Lattante et al., 2015). In addition, the
KEAP1-NRF2 signaling pathway and oxidative response has been
shown to be disrupted by SQSTM1 mutations (Deng et al., 2019;
Foster et al., 2019), a pathway originally found to be dysregulated
in SOD1-ALS (Kirby et al., 2005), which was subsequently
implicated in sALS (Sarlette et al., 2008). Finally, it has recently
been shown that SQSTM1 co-localizes with misfolded MAPT
and degrades the insoluble forms of the protein (Xu et al.,
2019). In transgenic rTg4510mutantMAPTmice, AAV-SQSTM1
was administered to increase SQSTM1 protein expression and
this resulted in reduced mutant insoluble MAPT and improved
pathology, including reduced astrogliosis and microgliosis.
FTDALS4: TANK-Binding Kinase (TBK1)
TBK1 mutations were first linked to ALS (Cirulli et al., 2015;
Freischmidt et al., 2015), FTD (Gijselinck et al., 2015; Le Ber et al.,
2015) and ALS-FTD in 2015 (Pottier et al., 2015). Loss of function
(LoF) mutations, including frameshifts, splice-site alterations,
read-throughs and nonsense mutations have been reported to
show definite or probable pathogenicity. The pathogenicity of
missense mutations is less certain as some have also been found
in controls (van der Zee et al., 2017) but such mutations in
functional domains which impair target protein binding, or target
or TBK1 phosphorylation, can also cause loss of function at the
protein level (Freischmidt et al., 2015; Pozzi et al., 2017; van der
Zee et al., 2017; de Majo et al., 2018). In addition, both LoF and
missense mutations increase the risk of ALS/FTD (odds ratio
11.78 and 1.62, respectively) (Cui et al., 2018).
The mutation frequency of TBK1 in ALS, FTD and ALS-FTD
is reported to be from 0.4 to 1.7% (Gijselinck et al., 2015; van
der Zee et al., 2017). More recently, a meta-analysis found LoF
mutations in 1.0% andmissense mutations in 1.8% of ALS and/or
FTD, and suggests a higher prevalence in European populations
compared to Asian populations (Cui et al., 2018). A separate
paper also showed TBK1 mutations to be the most important
cause of ALS-FTD after C9orf72 (Dols-Icardo et al., 2018).
TBK1 codes the TBK1 (TANK-binding kinase 1) protein,
a kinase which binds and phosphorylates proteins involved in
innate immunity (Pilli et al., 2012), autophagy (Korac et al.,
2013), and mitophagy (Heo et al., 2015). Protein targets include
optineurin (OPTN) (ALS12) and p62 (SQSTM1) (FTDALS3), two
ALS-FTD associated genes (Maruyama et al., 2010; Rea et al.,
2014) andmutations in both of these genes have been found along
with TBK1 mutations in patients (Pottier et al., 2015; Borghero
et al., 2016; Dols-Icardo et al., 2018; Lattante et al., 2019).
TBK1 mutations have also been identified alongside the
C9orf72 expansion (Gijselinck et al., 2015; van der Zee et al.,
2017), and mutations in FUS (Lattante et al., 2019), TARDBP
(Freischmidt et al., 2015; de Majo et al., 2018), or DCTN1
and FUS together (Muller et al., 2018). Interestingly, those
harboring TBK1 and TARDBP (de Majo et al., 2018) or TBK1
and FUS (Freischmidt et al., 2015) mutations, showed earlier
disease onset than those with TBK1 alone (Freischmidt et al.,
2015; Pozzi et al., 2017). One case showing TBK1 and C9orf72
mutations had a later disease onset; however, this was attributed
to a shorter C9orf72 expansion size of 59 repeats and variable
penetrance of the TBK1 mutation (Gijselinck et al., 2015). No
further genotype-phenotype associations have been identified
between TBK1mutation type or position, and clinical phenotype.
Mutations occur throughout the TBK1 gene, though missense
variants cluster within the kinase and ubiquitin like domains (de
Majo et al., 2018). TBK1-linked clinical phenotypes show variable
age of onset, different rates of progression, and survival length
(Gijselinck et al., 2015; Borghero et al., 2016; Pozzi et al., 2017; van
der Zee et al., 2017; de Majo et al., 2018; Weinreich et al., 2019).
Cyclin F (CCNF)
Mutation ofCCNF was first identified using genome-wide linkage
followed by exome sequencing within a large ALS-FTD pedigree
(Williams et al., 2016). Subsequently additional variants in both
ALS and FTD cases were identified accounting for 0.6–3.3% of
fALS-FTD patients among different populations (Williams et al.,
2016; Pan et al., 2017). Cyclin F, encoded by CCNF, is one
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of the components of an E3 ubiquitin-protein ligase complex
also known as SCFCyclinF (Skp1-Cul1-F-box E3 ubiquitin ligase
complex) (Galper et al., 2017). Mutation of CCNF in neuronal
cells causes errors in ubiquitination leading to ubiquitinated
protein accumulation of SCFCyclinF and TDP-43 as well as
impairment of autophagosome-lysosome fusion (Williams et al.,
2016; Lee et al., 2018). Recently, a CCNF mutation in a zebrafish
model has been shown to have disrupted axonal outgrowth
(Galper et al., 2017; Hogan et al., 2017). Further support for
CCNF as an ALS-FTD gene comes from the finding that
CCNF interacts with valosin containing protein (VCP) (ALS14),
increasing VCP’s ATPase activity, which in turn promotes TDP-
43 aggregation (Yu et al., 2019). Thus, for the purposes of this
review, CCNF is described as FTDALS5.
ALS GENES SUBSEQUENTLY
ASSOCIATED WITH ALS-FTD AND FTD
There are many genes which have been characterized as
causative for ALS where potentially pathogenic variants have
also been described in FTD cases. Whilst this is rare, the co-
occurrence of ALS and FTD being associated with mutations
in these genes further strengthens the genetic linkage between
these two disorders. These genes encode proteins associated
with autophagy/ubiquitin proteasome system (UPS) or RNA
processing. The exception is TUBA4A, which encodes a
microtubule associated protein. In addition, intermediate CAG
repeat expansions inATXN2 have been reported as a risk factor in
ALS and ALS-FTD and a disease modifier in both ALS and FTD.
ALS6: Fused in Sarcoma (FUS)
Fused in srcoma was initially identified as part of a fusion
oncogene, FUS-CHOP, resulting from a t(12;16) (q13;p11)
translocation event in malignant liposarcoma (Crozat et al., 1993;
Rabbitts et al., 1993). Located at chromosome 16p11.2, FUS
encodes a predominantly nuclear DNA/RNA binding protein
which belongs to the FET protein family. As a functional
component of the hnRNP complex, FUS is involved in many
RNA processing activities, including transcription regulation,
RNA transport and trafficking, pre-mRNA splicing, and miRNA
processing. FUS consists of 15 exons which encode 526 amino
acids. FUS has a multidomain structure consisting of an
N-terminal glutamine-glycine-serine-tyrosine (QGSY) domain,
three arginine-glycine-glycine rich domains (RGG1-3), an RRM,
zinc finger motif (ZnF), and a highly conserved C-terminal NLS
(Deng et al., 2014).
Mutations in FUS were first associated with autosomal
recessive fALS, with additional screening revealing mutations
in FUS to be causal in autosomal dominant ALS (Kwiatkowski
et al., 2009; Vance et al., 2009). Further studies have shown
that FUS mutations account for approximately 4% of fALS
cases, and 1% of sALS cases. The vast majority of mutations
are missense, with in-frame insertions and deletions occurring
rarely. Although ALS-associated mutations occur throughout
the whole length of the gene, most mutations are located in
exons 3–6, encoding the N-terminal transcriptional activation
domain, QGSY, and the nucleic acid binding domain RGG1,
or in exons 12–15 which encode C-terminal nuclear binding
domains RGG2 and RGG3, a ZnF domain and an NLS domain
(Deng et al., 2014). Mutations within exons 12–15 have been
found to be functional, whilst those in exons 3–6, which are also
more commonly found in sALS, do not always segregate with
disease. This indicates the presence of non-pathogenic variations,
and incomplete penetrance, highlighting the complexity of the
role of FUS in ALS pathogenesis. Screening of FTD patients
subsequently identified several FUS mutations in patients with
bv-FTD either with or without concurrent ALS though the
frequency of FUSmutations is much rarer in FTD than ALS cases
(Ticozzi et al., 2009; Blair et al., 2010; Van Langenhove et al., 2010;
Huey, Ferrari et al., 2012).
Fused in srcoma plays an important role in RNA processing.
Therefore, mutations in FUS have a negative impact on RNA
transcription, alternative splicing, and mRNA transport and
stabilization. It is evident that this results in widespread neuronal
dysfunction, contributing to the ALS phenotype, although, how
this occurs is not well understood. Several theories have been
proposed, including gain- and loss-of-function mechanisms
(Deng et al., 2014). Wild-type FUS is predominantly located
in the nucleus, however, disease-causing mutations in the
C-terminal NLS of FUS, including the most common FUS
mutation, p.R521C, leads to FUS-positive neuronal cytoplasmic
inclusions. The accumulation of FUS aggregates has been found
in the neuronal cytoplasm and dendrites of ALS and FTLD
patients. This disruption of nuclear import may result in toxic
gain of cytoplasmic function and loss of nuclear function (Deng
et al., 2014; Lopez-Erauskin et al., 2018). FUS inclusions have
also been found in atypical FTLD cases (aFTLD-U) as one of the
proteins in the ubiquitinated neuronal inclusions, as well as being
found in glial cells (Neumann et al., 2009). None of these cases
had mutations in the FUS gene.
Fused in srcoma was first found to have a role in RNA
transcription when nuclear depletion of RNA polymerase II
(RNAPII) resulted in an increase in cytoplasmic FUS (Zinszner
et al., 1997). Further studies demonstrated the role of FUS in pre-
mRNA splicing. FUS mediates the interaction between RNAPII
and U1 snRNP, a splicing factor responsible for recognizing
the 5′ splice junction (Yu and Reed, 2015). Beyond this, FUS
has been identified as component of the spliceosome, and also
interacts with other important splicing factors such as hnRNPA1
(Rappsilber et al., 2002; Zhou et al., 2013; Kamelgarn et al.,
2016). Loss of FUS functionality affects the splicing of its target
genes, contributing to widespread splicing dysfunction of genes
involved in neuronal functions, such as PPP2R2C which is
required for neurogenesis and ACTL6B which has a role in
dendritic development (Reber et al., 2016). Beyond this, FUS
mutations also result in the mislocalisation of U1 snRNP to the
cytoplasm, and the aggregation of FUS, hnRNPA1, hnRNPA2
and SMN1 into stress granules (Takanashi and Yamaguchi, 2014;
Yu et al., 2015).
Transcriptome analysis of human MNs generated from
mutant FUS iPSCs, identified changes in expression levels of
genes involved in cellular processes which have previously
been associated with neurodegenerative disease, including cell
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adhesion. Also, TAF15 which is also a member of the
FET family was found to be differentially expressed in FUS
mutant MNs (De Santis et al., 2017). More recently, mutant
FUS has been shown to affect important processes vital for
neuronal functionality in mice. Studies using transgenic mice
demonstrated that ALS/FTD-linked mutant FUS accumulates
within axons, reducing intra-axonal translation which, in turn,
causes early activation of the integrated stress response (ISR) and
increased phosphorylation of eIF2α. Ultimately, this inhibits the
protein synthesis of important RNAs, including those encoding
ion channels and transporters essential for synaptic function
(Lopez-Erauskin et al., 2018). Furthermore, suppressed protein
synthesis and disrupted regulation of nonsense medicated decay
was detected in fibroblast cells derived from FUS-related ALS
cases (Kamelgarn et al., 2018).
ALS10: TAR DNA Binding Protein
(TARDBP)
TARDBP is located on chromosome 1p36.22 and encodes
the transactive response DNA-binding protein 43 (TDP-43).
Like FUS, TDP-43 is a predominantly nuclear DNA/RNA
binding protein which is a member of the heterogeneous
nuclear ribonucleoprotein (hnRNP) family (Sreedharan et al.,
2008). The TARDBP gene consists of 6 exons, and has a
similar structure to FUS; an N-terminal domain (NTD), 2
RNA recognition motifs (RRM1-2) which are involved in RNA
and DNA binding, a nuclear localization signal and nuclear
export signal, and a C-terminal glycine-rich domain (GRD)
which is responsible for protein–protein interactions (Lagier-
Tourenne et al., 2010; Baralle et al., 2013). TDP-43 was initially
recognized as a transcription repressor protein which binds
to the TAR regulatory element of human immunodeficiency
virus-1 (HIV-1) (Ou et al., 1995). Further investigations
have shown that TDP-43 has other important roles in RNA
processing, including RNA transcription, pre-mRNA and pre-
miRNA splicing, RNA transport and mRNA stability (Scotter
et al., 2015).
Mutations in TARDBP are responsible for 4–5% of fALS
cases and 1% of sALS cases, and are inherited in an autosomal
dominant manner (Millecamps et al., 2010). TARDBP mutations
cause an ALS phenotype consisting of classic ALS symptoms.
Mutations in TARDBP have also been reported in patients with
FTD, with and without ALS (Benajiba et al., 2009; Borroni et al.,
2009; Kovacs et al., 2009; Pesiridis et al., 2009). The frequency
of TARDBP mutations in patients with FTD is estimated at 1%,
the majority presenting with bvFTD, though some patients do
present with svFTD or nfvFTD at onset (Caroppo et al., 2016).
The majority of mutations are located in exon 6, which
encodes the aggregation-prone C-terminal GRD. These
mutations increase the aggregation potential of this protein.
Ubiquitinated aggregates of TDP-43 are found in the cytoplasm
of MNs of ALS and FTD patients, not just patients with TARDBP
mutations (Neumann et al., 2006; Mackenzie and Rademakers,
2008; Johnson et al., 2009; Kirby et al., 2010). Given that 97%
of fALS and sALS patients are positive for TDP-43 cytoplasmic
inclusions, it is evident TDP-43 plays an important role in MN
degeneration and disease pathogenesis (Sreedharan et al., 2008;
Qin et al., 2014). In addition, TDP-43 positive inclusions are also
found in 50% of FTLD cases (Neumann et al., 2006; Mackenzie
et al., 2010). Although it is unknown how this occurs, it has been
hypothesized that this may be due to toxic gain of cytoplasmic
function and loss of nuclear function (Kabashi et al., 2010).
TDP-43 is functionally homologous to FUS and also
has important functions in RNA metabolism. Mutations in
TARDBP result in aberrant RNA processing on multiple levels;
transcription regulation, alternative splicing and mRNA stability
(Buratti and Baralle, 2008). Beyond regulating its own expression
level by binding to the 3′ untranslated region (3′ UTR) of
its mRNA, TDP-43 is also essential for maintaining normal
expression levels and splicing patterns of over 1,000 mRNAs
(Ayala et al., 2008; Polymenidou et al., 2011). Specifically,
TDP-43 dysfunction results in the dysregulated expression of
other ALS-associated proteins which also have roles in RNA
metabolism, including FUS, ATXN2, and progranulin (PGRN)
(Polymenidou et al., 2011; Sephton et al., 2011; Highley et al.,
2014). Furthermore, dysfunction of TDP-43 results in defective
alternative splicing of its target genes, including hnRNAPA1,
which negatively impacts cellular stability (Butti and Patten,
2018). Additionally, TDP-43 is involved in the splicing of cryptic
exons of particularmRNAs, such asATG4B (autophagy related 4B
cysteine peptidase). Splicing of cryptic exons produces aberrant
mRNA products. These have been observed in the CNS of
ALS and FTD patients and have been recently been linked
to impaired autophagy (Ling et al., 2015; Torres et al., 2018).
It is known that TDP-43 is a component of stress granules,
but how this contributes to the ALS phenotype is unknown
(Aulas and Vande Velde, 2015).
ALS12: Optineurin (OPTN)
Amyotrophic lateral sclerosis-associated mutations in OPTN,
which was previously implicated in glaucoma, were first
identified in 2010 in six affected members of a Japanese
pedigree with consanguineous marriages presenting with three
different types of mutations: a homozygous deletion of
exon 5, a homozygous nonsense p.Q398X mutation and a
heterozygous missense p.E478G mutation (Maruyama et al.,
2010). Subsequently, more than 20 mutations have been
described although not all have been investigated in in vitro and
in vivo disease models. The incidence of OPTN mutations in
FTD is still under debate, as one study reported copy number
variants inOPTN in 4.8% of FTD cases (Pottier et al., 2015) while
another study, recruiting a larger cohort of 371 FTD cases, did not
detect any mutations using whole exome sequencing (Rollinson
et al., 2012). More recently, a patient with ALS-FTD was reported
with compound heterozygous mutations, resulting in a 75–80%
reduction in OPTN (Pottier et al., 2018).
OPTN is a highly conserved hexameric protein that is
ubiquitously expressed with significantly high expression in
skeletal muscles (Toth and Atkin, 2018). OPTN is known to
interact with TBK1 (FTDALS4); in fact, a series of evolutionarily
conserved serine residues precedes the hydrophobic core
sequence in OPTN which bears homology to TBK1-binding
site of TANK, another substrate of TBK1 (Wild et al., 2011).
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FIGURE 2 | Pathogenic pathways associated with genetic variants of ALS. ALS is a complex disease affecting multiple interconnecting cellular pathways and
dysfunction of these pathways has been associated with many of the genetic mutations. Proposed aberrant mechanisms include abnormal nucleocytoplasmic
transport of RNA and RNA binding proteins (RBP) and altered RNA metabolism resulting from mislocalisation of RBPs. Mutations in RBP can undergo liquid-liquid
phase separation thereby altering stress granule formation and propagating cytoplasmic protein aggregation. Overload of these misfolded proteins could burden the
proteasome-ubiquitin system affecting timely clearance of abnormal proteins and downstream processes such as autophagy. Protein aggregation could influence
microtubule dynamics resulting in abnormal anterograde and retrograde axonal transport of vesicular cargoes and mitochondria. See text for full information on how
each of these genes associates with the mechanism shown. Glu, glutamate; genes in bold and italic, ALS-FTD genes;∗ = genes only associated with ALS and the
remainder are associated with ALS and FTD in differing proportions. Created using Biorender.com.
OPTN is involved in several cellular functions including
autophagy, vesicular trafficking, Golgi maintenance [as evident
from Golgi apparatus fragmentation in spinal motor neurons
and glia in post mortem tissue obtained from an ALS-FTD
patient (Kamada et al., 2014) and neuroinflammation (Toth
and Atkin, 2018; McCauley and Baloh, 2019)]. OPTN has also
been shown to regulate NFκB signaling wherein ALS associated
mutations in OPTN showed increased immunoreactivity
of microglia (McCauley and Baloh, 2019). OPTN-positive
cytoplasmic inclusions in the CNS are not only seen in
cases with OPTN mutations, but also in C9orf72, FUS,
and SOD1-related cases (Bury et al., 2016). Interestingly,
conditional loss of OPTN by Cre-loxP system in different
cell types using a murine model (Cnp-cre, Lyz2-cre, Gfap-cre,
and Mnx1-cre mice) showed RIPK1-mediated necroptosis
resulting in axonal myelination pathology when OPTN was
depleted in oligodendrocytes and myeloid cells, whereas no
pathology was observed when OPTN expression was selectively
removed in astrocytes and motor neurons (Ito et al., 2016),
further confirming non-cell autonomous toxicity in driving
neurodegeneration.
ALS15: Ubiquilin 2 (UBQLN2)
Mutations in UBQLN2, which is localized on the X chromosome,
were first identified in large ALS-FTD family in 2011 (Deng
et al., 2011). Four mutations located within the proline-X-X
(PXX) repeat region of the protein were subsequently found
through additional screening of fALS cases with no male to
male transmission. Further variants within or adjacent to the
PXX repeat region have been identified in ALS, FTD, or ALS-
FTD patients, though at rare frequencies (Williams et al.,
2012; Gellera et al., 2013; Ugwu et al., 2015). As a member
of the ubiquilin family, the protein is actively associated in
the degradation of misfolded and redundant proteins through
macroautophagy and the ubiquitin-proteasome system (Renaud
et al., 2019). Mutations cause defective binding to the proteasome
leading to interruption of the protein degradation, triggering
mislocalisation of OPTN from Rab-11 positive endosomal
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FIGURE 3 | Pathogenic pathways associated with genetic variants of FTD. FTD is a complex disease attributed to multiple genetic mutations affecting several
cellular pathways. Many of the proteins encoded by these genes are found to be aggregated into inclusions. Overload of these misfolded proteins might impair the
proteasome and autophagy, affecting timely clearance of abnormal proteins. Microtubule dysfunction results in abnormal anterograde and retrograde axonal
transport of vesicular cargoes and mitochondria and axonal degeneration. Decreased mitochondrial membrane potential (MMP) could damage mitochondrial
function and subsequently promote exiting of TDP-43 from the nucleus contributing to cytoplasmic TDP-43 inclusions. RNA processing and nucleocytoplasmic
transport defects impact upon many cellular pathways, depending on the regulatory RNAs and proteins being affected. Mutations in FTD-related genes such as
progranulin (GRN) could promote inflammatory response by microglia which is toxic to neuronal health. Genes in bold and italic = ALS-FTD genes,∗ = genes only
associated with FTD and the remainder are associated with ALS and FTD in differing proportions. Created using Biorender.com.
vesicles as well as loss of binding of UBQLN2 to hnRNP
proteins, including hnRNPA1 (ALS20) resulting in impaired
RNAmetabolism (Chang and Monteiro, 2015; Gilpin et al., 2015;
Osaka et al., 2015). ALS-linked mutations in UBQLN2 gene
were also found to be associated with dysfunction of autophagy,
neuroinflammation, as well as the formation of stress granules,
where mutations disrupted interaction with FUS (ALS6) and
FUS-RNA complexes (Picher-Martel et al., 2015; Hjerpe et al.,
2016; Alexander et al., 2018; Dao et al., 2018; Renaud et al., 2019).
ALS22: Tubulin Alpha 4A (TUBA4A)
Mutations in Tubulin alpha 4A (TUBA4A) were identified as
a very rare cause of ALS following the discovery of non-
synonymous variants during whole exome sequencing of fALS
index cases (Smith et al., 2014). Whilst patients had spinal-onset
ALS, two cases developed FTD, whilst a third case had FTD
in a first degree relative. Additional studies identified further
cases of FTD and ALS with mutations in TUBA4A, though
they were exceptionally rare, whilst other papers failed to find
any TUBA4A mutations in ALS or FTD cohorts (Dols-Icardo
et al., 2016; Perrone et al., 2017; Li et al., 2018). TUBA4A
encodes an alpha tubulin subunit which combines with other
alpha and beta tubulins to form microtubules. Mutant TUBA4A
proteins showed altered incorporation intomicrotubules, thereby
reducing the stability of the microtubule network in a dominant
negative manner (Smith et al., 2014). Interestingly, a study
identifying miR-1825 as decreased in both serum and plasma
of sALS and fALS, was shown to directly target tubulin-
folding co-factor b (TBCB) expression and this was associated
with depolymerisation and degradation of TUBA4A protein
in HEK293 cells (Helferich et al., 2018). Additional studies in
zebrafish embryos expressing human TBCB displayed reduced
levels of the TUBA4A zebrafish homolog and reduced axonal
length and branching, whilst TBCB and TUBA4A proteins levels
were inversely correlated in post-mortem brain cortex of fALS
and sALS. Thus, TUBA4A is implicated not only through genetic
mutations, but also by dysregulation of an upstream miRNA in
both fALS and sALS cases.
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TABLE 2 | Clinical phenotypes also associated with ALS and FTD related genes.
ALS loci Gene name Alternative clinical phenotypes Inheritance
FTDALS2 CHCHD1 SMA, Jokela type (SMAJ); Myopathy isolated mitochondrial, autosomal dominant (IMMD) AD AD
FTDALS3 SQSTM1 Paget disease of bone 3 (PDB3); Myopathy, distal, with rimmed vacuoles (DMRV);
Neurodegeneration with ataxia, dystonia and gaze palsy, childhood onset (NADGP)
AD AD AR
FTDALS4 TBK1 Encephalopathy, acute, infection-induced 8 (IIAE8) (susceptibility to) AD
ALS1 SOD1 Spastic tetraplegia and axial hypotonia, progressive (STAHP) AR
ALS2 ALS2 Primary lateral sclerosis, juvenile (PLSJ); Spastic paralysis, infantile onset ascending (IAHSP) AR AR
ALS4 SETX Spinocerebellar ataxia, with axonal neuropathy 2 (SCAN2) AR
ALS5 SPG11 Spastic paraplegia 11 (SPG11); Charcot-Marie-Tooth disease, axonal, type 2X (CMT2X) AR AR
ALS6 FUS Tremor, hereditary essential 4 (ETM4) AD
ALS8 VAPB Spinal muscular atrophy (SMA), late onset, Finkel type (SMAFK) AD
ALS11 FIG4 Charcot-Marie-Tooth disease, type 4J (CMT4J); Yunis-Varon syndrome Polymicrogyria, bilateral
temporo-occitpital (BTOP)
AR AR AR
ALS12 OPTN Glaucoma, primary open angle (POAG); Glaucoma, normal tension (susceptibility to) AD
ALS13 ATXN2 Spinocerebellar ataxia 2 (SCA2); Parkinson’s disease, late onset (susceptibility to) AD AD
ALS14 VCP Charcot-Marie-Tooth disease, type 2Y (CMT2Y); Inclusion body myopathy with early onset Paget
disease and frontotemporal dementia 1 (IBMPFD1)
AD AD
ALS16 SIGMAR1 SMA, distal, autosomal recessive 2 (DSMA2) AR
ALS20 hnRNPA1 Inclusion body myopathy with early onset Paget disease and frontotemporal dementia 3 (IBMPFD3) AD
ALS24 NEK1 Short-rib thoracic dysplasia 6, with or without polydactyly (SRTD6) AR
ALS25 KIF5A Spastic paraplegia 10 (SPG10); Myoclonus, intractable, neonatal (NEIMY) AD AD
Data obtained from Gene-Phenotype relationship data available on OMIM (http://www.ncbi.nlm.nih.gov/omim).
ALS13: Ataxin 2 (ATXN2)
A CAG repeat expansion encoding a polyglutamine repeat
is found in ataxin 2 (ATXN2), a ubiquitously expressed
protein involved in RNA processing, stress granule formation,
endocytosis, calcium signaling and controlling metabolism and
energy balance. In the normal population, the size varies
between 13 and 31 CAG repeats, though 22–23 repeat are the
most common (Velazquez-Perez et al., 2017). Repeats of over
35 are associated with fully penetrant spinocerebellar ataxia
2, with those 32–34 showing variable penetrance. Following
identification that ATXN2 interacts with TDP-43, intermediate
repeats of 27–33 were found to be a risk factor for ALS (Elden
et al., 2010), with the intermediate CAG repeat interrupted with a
CAA codon (Corrado et al., 2011). Subsequently, a meta-analysis
of 9 studies highlighted that whilst there was an increased risk of
ALS from 29 CAG/CAA repeats, significance was only reached
for 31–33 repeats (Neuenschwander et al., 2014). Interestingly,
repeat sizes of 27–28 were found to lower risk of ALS. More
recently, a meta-analysis of 16 published studies, along with two
large unpublished cohorts of ALS demonstrated an increased risk
of ALS with 29–32 CAG/CAA repeats, and this risk increased
with the number of repeats (Sproviero et al., 2017). This study
also found 27 repeats to have a protective effect.
Following the link with ALS, the role of ATXN2 intermediate
repeats in FTD was investigated. Screening of ALS and FTD
alongside other neurodegenerative diseases identified 30–33
repeats to be associated with ALS but not FTD (Ross et al., 2011).
Subsequently, ATXN2 CAG repeats of ≥29 were also found to
be associated with ALS and familial ALS-FTD but not sporadic
ALS-FTD or FTD (Lattante et al., 2014). A further study of 368
cases also found no significant correlation between FTD and
ATXN2 CAG repeat size though they did find that intermediate
repeats (≥27) were associated with an earlier age at onset of FTD
(Rubino et al., 2019).
Screening of ATXN2 has also identified expansions >34 in
rare cases of both ALS (Corrado et al., 2011; Ross et al., 2011;
Van Damme et al., 2011) and FTD (Baumer et al., 2014; Fournier
et al., 2018) although no signs of ataxia were reported and
neuropathological examination confirmed a diagnosis of ALS. As
well as interacting with TDP-43, ATXN2 has also shown to bind
to mutant FUS, with intermediate repeats binding both WT and
mutant FUS proteins (Farg et al., 2013).
FTD GENES SUBSEQUENTLY
ASSOCIATED WITH ALS-FTD AND ALS
Several ALS genes identified through next generation sequencing
have previously been identified as being associated with FTD
or a syndrome incorporating FTD, such as inclusion body
myopathy with Paget’s disease of bone and frontotemporal
dementia (IBMPFD). These include VCP and CHMP2B.
ALS14: Valosin Containing Protein (VCP)
Mutations in VCP have been described in ALS, FTD and
inclusion body myopathy with Paget’s disease of bone and
FTD (IBMPFD) which is an adult onset disorder characterized
by muscle weakness, early onset PDB (see section “Cyclin
F (CCNF)”) and FTD, though episodic memory is preserved
(Kimonis, 1993). Mutations in VCP account for 1–2% of fALS
cases, are found to be rare in sALS (Koppers et al., 2012)
and whilst FTD is recognized in a third of IBMPFD patients,
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mutations have been found in FTD cases (Saracino et al., 2018;
Wong et al., 2018).
Valosin containing protein (also called as CDC48 or p97) is
a hexameric ATPase that is ubiquitously expressed and involved
in diverse cellular functions including autophagy, endoplasmic
reticulum (ER)- associated degradation (ERAD), chromatin
remodeling, DNA repair and other protein quality control
pathways (Wang et al., 2016; Shahheydari et al., 2017). ATPase
has two domains, D1 and D2 and a regulatory N-domain.
Amajority of the mutations inVCP have been documented in the
N-domain in patients with ALS and/or FTD (Abrahao et al., 2016;
Wang et al., 2016; Shahheydari et al., 2017) although additional
ALS and FTD mutations have been reported in the D1 domain
(Wong et al., 2018). A study reported that mutations in the
N-domain, an evolutionarily conserved region in VCP, results
in poor hexamer assembly and reduced small ubiquitin-like
modifier (SUMO)-ylation of VCP that diminishes its recruitment
to stress granules and consequently affects ERAD in a Drosophila
model of ALS/FTD. In contrast, a recent study that screened 48
patients with FTD reported identified 3 mutations that lie within
the D1 domain of VCP and are hypothesized to affect ATPase
binding activity (Wong et al., 2018). Interestingly, it has been
reported that VCP interacts with FUS (ALS6) (Wang et al., 2015)
and Cyclin F (CCNF) (proposed FTDALS5) (Yu et al., 2019)
both of which are implicated in ALS. Mutations in FUS/CCNF
were shown to increase ATPase activity of VCP in the cytoplasm,
causing VCP to mislocalize to the cytoplasm (Yu et al., 2019)
and trigger accumulation of polyubiquitinated proteins (Wang
et al., 2015). VCP is also vital inmitochondrial quality control and
IBMFTD patient fibroblasts carrying a mutation in VCP showed
uncoupling of mitochondria, reduced mitochondrial membrane
potential and ATP production (Bartolome et al., 2013), a feature
that is also evident in SIGMAR1 (ALS16) mutations.
ALS17: Chromatin Modifying Protein 2B
(CHMP2B)
Mutation of CHMP2B was initially identified in a large Danish
family with FTD linked to chromosome 3 (termed FTD-3)
(Skibinski et al., 2005). The splice site mutation c.532-1G > C
results in the formation of two transcripts encoding two different
proteins with a defective carboxyl terminus: CHMP2Bintron5,
where the intronic sequence between exons 5 and 6 is retained
and a single valine is incorporated instead of the final 36 amino
acids encoded by exon 6 and CHMP2Bdel10, where a cryptic splice
site is used 10 bp from exon 6, resulting in the insertion of 29
novel amino acids. Subsequently, a Belgian family with FTD-3
was identified, where the c.493C > Tmutation lead to truncation
of the protein, with the loss of 49 amino acids (van der Zee et al.,
2008). In contrast, mutations identified in CHMP2B that were
associated with ALS were missense mutations (Parkinson et al.,
2006).
CHMP2B is a component of the endosomal sorting complex
required for transport III (ESCRT-III) complex, which is involved
in the maturation of endosomes and autophagosomes. Using
cellular and animal models, mutations in CHMP2B (both
truncated and missense mutations) have been shown to disrupt
endosomal-lysosomal trafficking, through accumulation and
enlargement of endosomes (Cox et al., 2010; Zhang Y. et al.,
2017; Vandal et al., 2018). The pathology of FTD-3 cases is
distinguished by the presence of ubiquitin and p62 (SQSTM1;
FTDALS3) positive inclusions, which are negative for TDP-43
and Tau (Holm et al., 2007).
OTHER ALS AND FTD GENES
In addition to those genes described above, there are other
genes associated solely with fALS and fFTD, including “Pure”
ALS genes such as SOD1 and “Pure” FTLD genes MAPT and
Progranulin (Bennion Callister and Pickering-Brown, 2014).
However, it is notable that many of these pure ALS genes also
encode proteins that cluster into functional pathways associated
with ALS-FTD genes, with mutations in the pure ALS gene
affecting similar biological pathways. For example, numerous
genes are associated with autophagy/proteasome impairment
(C9orf72, SQSTM1, TBK1, OPTN, VCP, UBQLN2, and CHMP2B)
and/or their proteins are found to be aggregated in cytoplasmic
inclusions (C9orf72, SQSTM1, OPTN, VCP, UBQLN2, CCNF,
FUS, TDP-43, and CHMP2B) (Figure 2). Many of these genes
also encode proteins that have a role in RNA processing (C9orf72,
FUS, TARDBP, and UBQLN2), whilst others are associated with
and dysregulate the mitochondria (CHCHD10; TBK1; and VCP)
or the cytoskeleton (TUBA4A, CCNF, and SQSTM1). SOD1-ALS,
accounting for around 10% of fALS cases, is distinctive in that
it is not associated with TDP-43 inclusions, unlike the majority
of ALS cases. However, mutations in SOD1 are associated with
similar pathogenic mechanisms, such as disruption to protein
quality control, mitochondrial dysfunction, dysregulated axonal
transport and RNA processing, in addition to oxidative stress and
excitotoxicity. Due to the wide range of biological pathways, gene
silencing of SOD1 is currently in clinical trials as a therapeutic
strategy for SOD1-ALS patients (van Zundert and Brown, 2017).
Many of the additional ALS genes can also be categorized
into these pathways (Table 1 and Figure 2), such as SETX,
ANG, ATXN2, hnRNPA1, and MATR3, which are all involved
in RNA processing and SPG11, KIF5A, and PFN1 that are
associated with the cytoskeleton and mutations in which cause
axonal defects (Alsultan et al., 2016). Many of the genes also
encode proteins involved in trafficking components within the
cell, such as endosomes (ALS2, FIG4, and NEK1) or in the
unfolded protein response (VAPB and SIGMAR1). However, as
research has investigated the effect of mutations within these
genes, additional secondary pathways have been implicated,
such as mutant SOD1 protein’s effect on protein homeostasis,
gene expression and axonal transport, resulting in a complex
interactome of direct and indirect effects, which ultimately lead
to neurodegeneration.
Whilst there are far fewer genes associated with only FTD,
GRN (responsible for 5–20% of fFTD) and MAPT (responsible
for 10–20% of fFTD) are also involved in similar pathways
(Figure 3). The progranulin gene (GRN) encodes a secreted
glycoprotein that is taken up by the cell and cleaved into
multiple smaller granulins. The precise function of granulin is
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still to be determined, though it has been shown to be involved
in multiple pathways including neuronal survival, neurite
outgrowth, neuroinflammation, and autophagy (Olszewska et al.,
2016). Mutations in GRN, leading to haploinsufficiency, are
thought to cause FTD though lysosomal defects and reduced
clearance of proteins (Ferrari et al., 2019). As with ALS, TDP-
43 inclusions are also present, of the FTLD-TDP Type A form
(Mackenzie et al., 2011). MAPT, encoding the microtubule
associated protein tau, stabilizes microtubules through binding
to tubulin. Mutations in MAPT disrupt this binding and lead
to hyperphosphorylated tau aggregates. Recently, mutations
in the TATA-box-binding gene (TBP), normally associated
with spinocerebellar ataxia 17 (SCA17), were identified in
a patient with FTD whose MRI showed cerebellar atrophy
(Olszewska et al., 2019). The variant was found to co-segregate
with disease. Thus, this new FTD gene, which encodes a
transcription initiation factor can be categorized as an RNA
processing gene.
The identification of a novel gene in a pathway that has
not previously been associated with the genetics of ALS or
FTD is particularly valuable for highlighting new disease biology
and subsequently novel therapeutic targets. In this respect, the
identification ofmutations inGLT8D1 andDNAJC7 in fALS cases
are notable discoveries. GLT8D1 is a glycosyltransferase with
an enrichment of familial ALS-associated mutations proximal
to the substrate binding site (Cooper-Knock et al., 2019). It
was demonstrated that the mutations negatively impact enzyme
activity suggesting a loss of function mechanism. Whilst the
exact role of GLT8D1 remains to be discovered, however,
glycosyltransferases are known to be involved in the synthesis of
gangliosides which are signaling molecules important for motor
neuron function (Harschnitz et al., 2014). As such, it is perhaps
not surprising that glycosyltransferase dysfunction has already
been associated with other neurodegenerative diseases such as
Parkinson’s, Huntington’s and Alzheimer’s disease.
DNAJC7 encodes a heat shock protein (HSP40) which
alongside HSP70 facilitates protein homeostasis, through folding
new peptides and removing misfolded proteins. Rare protein
truncatingmutations were identified inDNAJC7 in ALS cases and
were absent from controls and subsequent screening identified
further loss of function mutations as well as several rare missense
mutations, predicted to be damaging (Farhan et al., 2020). In
fibroblasts from a patient with a p.Arg156Ter mutation, protein
levels were reduced, suggesting that these mutations may lead
to protein aggregation, a characteristic feature of ALS. Further
screening of DNAJC7 and GLT8D1 in additional cohorts of ALS,
ALS-FTD, and FTD cases will establish the contribution of these
genes and the roles of their proteins in disease pathogenesis.
CONCLUSION
Amyotrophic lateral sclerosis and FTD have been described as
forming a spectrum of disease, with converging mechanisms of
neurodegeneration involving RNA processing, stress granules,
protein aggregation and autophagy supporting this proposal
(Ling et al., 2013; Deng et al., 2017; Nguyen et al., 2019;
Baradaran-Heravi et al., 2020). However, it also clear that some
genes, such as MAPT, are quite distinct and therefore it is
argued that these should be kept separate (Hardy and Rogaeva,
2014). This distinction is also supported by the neuropathology,
as whilst the majority of genetic (and sporadic) ALS cases
have TDP-43-positive inclusions, along with C9orf72 and GRN-
FTD, MAPT- FTD does not, similar to SOD1-ALS. Thus, these
distinctions are important to consider when pursuing diagnostic
and prognostic biomarkers or therapeutic strategies.
The application of next generation sequencing, either in the
form of targeted, whole exome or whole genome sequencing
(WGS) has had a significant impact on the identification of genes
associated with these diseases. However, it is also: (i) broadening
the range of diseases that we see associated with variants in these
genes (Table 2), (ii) broadening the range of genes that you would
conventionally associate with ALS and FTD (Blauwendraat et al.,
2018; Tripolszki et al., 2019), (iii) increasing the frequency
of variants in known ALS and FTD genes within apparently
sporadic cases, highlighting the variable penetrance of many of
these proposedmutations (Tripolszki et al., 2019), (iv) identifying
multiple variants in disease-associated genes within an individual
(Cady et al., 2015), which will become increasingly important as
personalized medicine based on your genetic mutation enters the
clinic and finally (v) illustrating both the variability in frequencies
of known genes across populations worldwide (Majounie et al.,
2012; Wei et al., 2019), but also the inequality as the majority
of these studies are undertaken in the northern hemisphere. It
is hoped that WGS of large international cohorts of ALS and
FTD such as Project MinE2 and GENFI3 will begin to fully
understand the genetic contribution to disease and potentially
answer why individuals with a particular variant go on to develop
ALS, FTD or ALS-FTD.
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